Aliskiren
- TRADE NAMES: Rasilez (Novartis); Tekamlo (Novartis); Tekturna (Novartis); Tekturna HCT (Novartis); Valturna (Novartis)
- INDICATIONS: Hypertension
- CLASS: Antihypertensive, Renin inhibitor
- HALF-LIFE: 24 hours
ACE inhibitors, Aldosterone antagonists, Atorvastatin, Candesartan, Celecoxib, Cyclosporine, Diclofenac, Furosemide, Heparin, Irbesartan, Itraconazole, Ketoconazole, Losartan, Meloxicam, Moexipril, NSAIDs, Olmesartan, Potassium salts, Potassium-sparing diuretics, Sacubitril/Valsartan, Tinzaparin, Trandolapril, Verapamil
PREGNANCY CATEGORY: D
category C in first trimester; category D in second and third trimesters
Tekamlo is aliskiren and amlodipine; Tekturna HCT is aliskiren and hydrochlorothiazide; Valturna is aliskiren and valsartan.
Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
Contra-indicated for concomitant use with angiotensin receptor blockers or angiotensin-converting enzyme (ACE) inhibitors in patients with diabetes.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of aliskiren in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric